Industry Roundup: GMPs, DXM, Pharmascience, Rock Creek
This article was originally published in The Tan Sheet
Executive Summary
Herbal firm crosses GMP, claims lines; Kentucky makes 8 to age-restrict DXM sales; Pharmascience expands with Quebec support; Rock Creek closes share offerings; and more news in brief.
You may also be interested in...
In Brief: Federal Microbeads Bill Advances; Avon Buyout Hoax? More
The Microbead-Free Waters Act of 2015 was approved via voice vote by the House Energy and Commerce Health Subcommittee May14; Avon says it has not received a buyout offer from PTG Capital Partners despite a May 13 SEC filing from the firm indicating as much. More news in brief.
Between A Rock Creek And A Hard Place: Firm Stops Supplement Sales, Weathers Litigation
Rock Creek Pharmaceuticals faces investor and consumer class-action complaints on top of ending sales of its nutritionals following an FDA warning. Moreover, the company name is known more in connection with federal officials’ investigation of the former governor of Virginia than for its products.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”